L. Liang
机构：BeiGene (China)
发表论文 4 篇 · 总被引 50 次 · h-index 2
代表论文
- Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial (2024 · ESMO Open · 被引 44)
- 132P Randomized phase III study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC): RATIONALE-307 updated analysis (2022 · Immuno-Oncology Technology · 被引 5)
- Research on Demand Side Response Strategy of Active Distribution Network Considering User Satisfaction (2022)
- Turn-on Condition and Characteristics of High-power Semiconductor Switch RSD (2006 · 2006 5th International Power Electronics and Motion Control Conference)